The PROPHY-VAP Trial: Ceftriaxone to Prevent VAP in Patients with Acute Brain Injury
RebelEM
FEBRUARY 29, 2024
Limited to academic hospitals in one country, which may call generalizability into question. 11 Curiously, VAP in patients with traumatic head injury does not appear to increase mortality, but does increase ventilator time, ICU, and hospital length of stay. Mortality is variable by study, but ranges from 16-70%. El-Ebiary, M.;
122 
Let's personalize your content